By 2030, a diabetes prevention and treatment system will enable over 60% of residents aged 18 and above to be aware of the disease. By then, the coverage rate of standardized management services for type 2 diabetes patients at the primary level will exceed 70%, according to the documents released by multiple departments including the National Health Commission (NHC).

Abbott (NYSE: ABT) today announced U.S. Food and Drug Administration (FDA) clearance for two new over-the-counter continuous glucose monitoring (CGM) systems – Lingo™ and Libre Rio™, which are based on Abbott's world-leading FreeStyle Libre® continuous glucose monitoring technology1, now used by about 6 million people globally2. The newly cleared systems have been intentionally designed to meet different needs – Lingo for consumers who want to better understand and improve their health and wellness, and Libre Rio for adults with Type 2 diabetes who do not use insulin and typically manage their diabetes through lifestyle modifications.

An analysis conducted by an international research team has identified 13 biomarkers that may improve the accuracy of predicting the risk of cardiovascular disease (CVD) in people with type 2 diabetes.

Roche Holding AG will fold its stand-alone diabetes business into its broader diagnostics unit after a decade and a half of declining sales.

Enable Biosciences said on Tuesday that it has received a $3 million Phase IIB Small Business Innovation Research grant from the National Institute of Diabetes and Digestive and Kidney Diseases for its type 1 diabetes test.

Medtronic has received a CE mark for its continuous glucose monitoring (CGM) device, Simplera, allowing the device to be marketed in the European Union.

Abbott (NYSE: ABT) today announced it has completed the acquisition of Bigfoot Biomedical, a leader in developing smart insulin management systems for people with diabetes.

Abbott (NYSE: ABT) and WW International, Inc. (NASDAQ: WW), known as WeightWatchers, announced today the availability of a connected app to help people living with diabetes understand how food and activity impact their glucose levels.

Abbott (NYSE: ABT) and Bigfoot Biomedical today announced a definitive agreement for Abbott to acquire Bigfoot, a leader in developing smart insulin management systems for people with diabetes.

Renalytix has received De Novo marketing authorisation from the US Food and Drug Administration (FDA) for its KidneyIntelX.dkd prognostic test.